To reveal the potential of 3rd generation ADC made with PSARlink technology platform, the therapeutic area on which Mablink focuses is cancer.
Mablink develops its own drug candidates with PSARlink technology:
MBK-101
Research
Preclinical
Reg. Tox. studies
Phase I
Phase II
Acute myeloid leukemia
Preclinical
| Research | Preclinical | Reg. Tox. studies | Phase I | Phase II |
MBK-102
Research
Preclinical
Reg. Tox. studies
Phase I
Phase II
Non-Hodgkin's lymphoma
Preclinical
| Research | Preclinical | Reg. Tox. studies | Phase I | Phase II |